Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)

Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.

• Supplier: Selleck Chemicals
• Product #: A2697
• Sku #: A2697-1mg